9-Month EBITDA Margin Compression
Year-to-date EBITDA margin declined 150 bps to 37.6% from 39.1% in 9M FY25, reflecting integration costs and new facility ramp-up expenses. CFO acknowledged margin remains in 35-37% range.
SUDEEPPHRM / Q3-FY26 / risks
Keep the risk register visible.
Sudeep Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Battery Materials Revenue Timeline Gap
Despite 34 active customer engagements, battery materials will only begin contributing revenue in FY28, creating an 18-month gap before offtake translates to sales. Depreciation and interest will only hit from FY28.
Customer Approval Bottlenecks
Analyst raised question about customer volume uptake and working capital requirements. Management deflected working capital specifics, stating only that networking capital days remain at ~180 days without detailed inventory/receivables breakdown.
Greenfield Utilization Ramp Uncertainty
New Nandiseri facility faces 6-12 month customer approval cycles before material revenue contribution, with management explicitly stating FY28 as the year for meaningful scaling.